NCT07784881Completed
Deciphering the Self-antigen Specific T Cell Signature of Autoimmune Liver Diseases
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The study aims to establish the molecular signature of autoimmune self-antigen-specific T cells in AutoImmune Liver Disease (AILD)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 220 (actual)
- First submitted
- 20 Aug 2026
- Start date
- 20 Apr 2021
- Primary completion date
- 24 Oct 2025
- Lead sponsor
- Nantes University Hospital
- Diseases
- Primary biliary cholangitis
- NCT number
- NCT07784881
What you commit to
- Study type: Observational
- Participants enrolled: 220
- From 20 Apr 2021 to the primary completion date, 24 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV positive
- HBV infection Positive
- HCV serology positive and PCR positive
Who the study is looking for
- Patient informed consent
- AIH with no previous treatment whose diagnosis is validated by at least 2 of the following criteria:
- ALT\>2N or IgG\>1.1N
- Presence of autoantibodies : ANA (antinuclear), ML (anti-smooth muscle), SLA (anti-soluble liver antigen), LKM1 (anti-endoplasmic reticulum), LC1 (anti-liver cytosol)
- Presence of interface hepatitis on biopsy
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nantes University Hospital Coordinator of this site? Confirm its status | Nantes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.